Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Investors may react cautiously to news that LAURUSLABS's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 51.488724
debtToEquity 60.048000
earningsGrowth 12.130000
revenueGrowth 0.314000
grossMargins 0.546400
operatingMargins 0.169020
trailingEps 9.430000
forwardEps 23.370000

Laurus Labs Limited's forward PE ratio is too high, raising concerns that future price increases may be restricted and a correction could be imminent. It's essential to weigh this parameter carefully in conjunction with other fundamentals to get a clearer picture of the stock's valuation.
Positive earnings and revenue growth for LAURUSLABS suggest that the company is expected to grow its business. This trend reflects strong financial performance, with continued profitability and sales increases indicating a bright outlook for future expansion.
Laurus Labs Limited's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

Price projections for LAURUSLABS have consistently been revised upward, suggesting that analysts are increasingly optimistic about the company's performance. This trend reflects a positive outlook for LAURUSLABS's future.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


Analysts' sell bias for LAURUSLABS suggests caution, but investors should base their decisions on a wide range of market indicators. This ensures a more comprehensive view of LAURUSLABS's market potential and provides a better framework for making balanced investment decisions.